Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center), Bruno Sangro(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Tu Van Dao(Vietnam National Children's Hospital), В. В. Бредер, Robin Kate Kelley(University of California, San Francisco), Masatoshi Kudo(Kindai University), Alejandra Negro(AstraZeneca (Japan)), Stephen L. Chan(Chinese University of Hong Kong), Enrico N. De Toni(LMU Klinikum), Junji Furuse(Kyorin University), Kabir Mody(Mayo Clinic in Florida), Lorenza Rimassa(Humanitas University), Alexander Vasilyev(Russian Railways), Vincent C. Tam(University of Calgary), Wattana Sukeepaisarnjaroen(Khon Kaen University), Philip He(AstraZeneca (Japan)), George Lau(University of Hong Kong), Yoon‐Koo Kang(Ulsan College), Satheesh Chiradoni Thungappa(Sri Venkateshwaraa Medical College Hospital and Research Centre), Alexandra Heurgué(Hôpital Robert-Debré)
Cited by 398
Related Papers
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
|New England Journal of Medicine|2005|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k